 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The recalls were reported in the daily US Food and Drug Administration Recall Information updates on 21 August, 2023

Alembic, Aurobindo Pharma recall drugs from US market

ICICI Securities recommended reduce rating on Alembic Pharma with a target price of Rs 705 in its research report dated August 07, 2023.

Reduce Alembic Pharma; target of Rs 705: ICICI Securities

Nippon Life has seen a breakout of horizontal resistance trendline adjoining highs of June 30 and July 12, and formed a bullish candlestick pattern on the daily timeframe with above average volumes. Further, it has also seen a golden crossover this month.

Trade Spotlight | Your game plan for Alembic Pharma, Nippon Life, Gland Pharma today

The momentum is expected to take the index up to 19,000 mark in the coming days, with immediate support at 18,800, then 18,700-18,500 area, experts said

A look at top 10 bets for next 3-4 weeks as market rallies to record highs

KR Choksey is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 704 in its research report dated May 06, 2023.

Buy Alembic Pharma; target of Rs 704: KR Choksey

Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 550 in its research report dated May 06, 2023.

Neutral Alembic Pharma; target of Rs 550: Motilal Oswal

Alembic Pharma Consolidated March 2023 Net Sales at Rs 1,406.45 crore, down 0.66% Y-o-Y

The brokerage firm sees domestic branded formulations-focused firms' growth rate in the mid-teen range, driven by a high single-digit increase in prices 

Antique Broking bullish on Indian pharma market for FY24, stays negative on US generics 

Alembic Pharmaceuticals' share touched a 52-week high of Rs 792.30 on April 28, 2022 and a 52-week low of Rs 463.30 on March 29

Alembic Pharma shares up 5% on USFDA approval for glaucoma  drug

The company has received final approval from the US Food &amp; Drug Administration (USFDA) to market Brimonidine Tartrate Ophthalmic Solution, Alembic Pharmaceuticals said in a statement.

Alembic Pharma gets USFDA nod for generic ophthalmic solution

Alembic Pharmaceuticals Ltd. is a research and development pharmaceutical company, which engages in the research, development, manufacture, and market of generic and branded pharmaceutical products. The firm's businesses are Active Pharmaceutical Ingredients and Formulations. It focuses on the following therapeutic areas: Dermatology, Cardiology, Anti-Diabetic, Gastrology, Ophthalmology, Nephrology and Urology, Anti-Infective, Oncology, and cold and cough. The company was founded by Tribhuvandas Kalyandas Gajjar in 1907 and is headquartered in Vadodara, India.

Watchers	50
52-Wk Low	462.30
52-Wk High	826.75

Market Cap	149.64B
Volume (M)	100,273.00
52-Wk High	826.75
52-Wk Low	462.30

Current Price	761.30
Prev Close	752.20
Open	755.00
Dividend Yield	1.61%
50-Day Moving Average	755.52
Beta	0.09
Avg. Volume	191,453.91
PE Ratio	28.32

52-Week High	826.75
52-Week Low	462.30
Market Capitalization	149.64B
EPS	26.89
Price to Book	3.41
Revenue Per Employee	3.53M
Enterprise Value/EBITDA	11.64

APLLTD.NSE Alembic Pharmaceuticals Ltd

About

Feed

News

Fundamentals